TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:55
Aclaris Therapeutics Inc. ( ACRS ) https://www.aclaristx.com
2.92USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ACRS
172.43%
SPY
32.66%
-80.09%
ACRS
SPY
108.59%
ACRS
51.82%
SPY
302.52%
ACRS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
207.01
82.00
0.76
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.59
7.64
1.59
-22.37
0.00
-1.58
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-240.93
84.95
-374.15
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.7488
-71.62
-26.42
0.66
Other Earnings and Cash Flow Stats:
Aclaris Therapeutics Inc. ( ACRS ) Net Income TTM ($MM) is -37.00
Aclaris Therapeutics Inc. ( ACRS ) Operating Income TTM ($MM) is -46.30
Aclaris Therapeutics Inc. ( ACRS ) Owners' Earnings Annual ($MM) is 0.00
Aclaris Therapeutics Inc. ( ACRS ) Current Price to Owners' Earnings ratio is 0.00
Aclaris Therapeutics Inc. ( ACRS ) EBITDA TTM ($MM) is -45.39
Aclaris Therapeutics Inc. ( ACRS ) EBITDA Margin is -374.15%
Capital Allocation:
Aclaris Therapeutics Inc. ( ACRS ) has paid 0.00 dividends per share and bought back -0.573797 million shares in the past 12 months
Aclaris Therapeutics Inc. ( ACRS ) has increased its debt by 0.566 million USD in the last 12 months
Capital Structure:
Aclaris Therapeutics Inc. ( ACRS ) Interest-bearing Debt ($MM) as of last quarter is 2
Aclaris Therapeutics Inc. ( ACRS ) Annual Working Capital Investments ($MM) are 6
Aclaris Therapeutics Inc. ( ACRS ) Book Value ($MM) as of last quarter is 130
Aclaris Therapeutics Inc. ( ACRS ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
Aclaris Therapeutics Inc. ( ACRS ) has 47 million in cash on hand as of last quarter
Aclaris Therapeutics Inc. ( ACRS ) has 18 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aclaris Therapeutics Inc. ( ACRS ) has 71 common shares outstanding as of last quarter
Aclaris Therapeutics Inc. ( ACRS ) has 0 million USD of preferred stock value
Academic Scores:
Aclaris Therapeutics Inc. ( ACRS ) Altman Z-Score is -3.94 as of last quarter
Aclaris Therapeutics Inc. ( ACRS ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Aclaris Therapeutics Inc. ( ACRS ) largest shareholder is owning shares at 0.00 ($MM) value
Mehra Anand(an insider) Bought 666666 shares of Aclaris Therapeutics Inc. ( ACRS ) for the amount of $1499998.50 on 2024-11-19
2.65% of Aclaris Therapeutics Inc. ( ACRS ) is held by insiders, and 77.82% is held by institutions
Aclaris Therapeutics Inc. ( ACRS ) went public on 2015-10-07
Other Aclaris Therapeutics Inc. ( ACRS ) financial metrics:
FCF:-18.50
Unlevered Free Cash Flow:0.00
EPS:-0.43
Operating Margin:-240.93
Gross Profit Margin:84.95
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-23.31
Beta:0.66
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Aclaris Therapeutics Inc. ( ACRS ) :
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.